Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain.
about
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilitiesChemical probes of endocannabinoid metabolismTherapeutic potential of monoacylglycerol lipase inhibitorsMonoacylglycerol lipase - a target for drug development?Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applicationsPeripheral gating of pain signals by endogenous lipid mediators.Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout miceChemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoidsThe neurobiology of cancer pain.Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands.Peroxisome proliferator-activated receptor α mediates acute effects of palmitoylethanolamide on sensory neuronsJZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy.Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.High-Intensity Swimming Exercise Decreases Glutamate-Induced Nociception by Activation of G-Protein-Coupled Receptors Inhibiting Phosphorylated Protein Kinase A.The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model.Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer painThe non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer painCannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation.Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6.In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects.Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids.No more pain upon Gq-protein-coupled receptor activation: role of endocannabinoids.Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.The evolving role of the endocannabinoid system in gynaecological cancer.The cannabinoid system and pain.WWL70 protects against chronic constriction injury-induced neuropathic pain in mice by cannabinoid receptor-independent mechanisms.Tingenone, a pentacyclic triterpene, induces peripheral antinociception due to cannabinoid receptors activation in mice.Sensitization of C-fiber nociceptors in mice with sickle cell disease is decreased by local inhibition of anandamide hydrolysis.
P2860
Q24623282-91BA0EE7-AA9E-4E5D-B064-AEFE905AE16BQ26863202-8E909C5F-928D-47E5-A01E-E8CEF1796204Q26991513-FE643687-F53F-48D6-A9A9-25345CC3A3CEQ26998964-13AC9EB9-2F19-433C-93F0-19DDCE16C875Q28300390-4BB92CE8-1D11-4235-9FF3-A5EE5C2B0D41Q33608432-CEB5B1A4-49D3-483A-AB3D-B8F6FB932C6FQ33943990-7E991C4B-C4D2-4753-B1F2-D2F57EF8A3DAQ34156640-A7598354-BD69-4E9A-8FE1-04350C62C720Q34167635-6731982F-1A7E-4625-94A3-5ECD9CD13160Q34233536-8ADE4C03-B7DB-4485-9215-529585BA68AAQ34642573-A602CA8D-8F70-4CB6-B6D1-FC6DFF7EE251Q34715335-65D38A43-42B7-4F6A-B9E7-5E38531D0A70Q35138445-E58D26BF-84BE-4BD7-BFF9-ADBEF59D19B6Q36006338-563AA7A3-EFD5-4DF1-9E6D-43D4CE074BEAQ36131752-4F69D390-E11A-425A-A8C2-66D9A7B2AE52Q37030457-D7A81D11-5D4F-4294-A088-F7D7358125B8Q37107118-8F64EA13-8697-45E7-BE85-918B597F9E4AQ37120771-1838A021-FE9C-4DF3-8FAA-7C0EA57F4B7EQ37216210-209F8D07-21C4-489C-8D32-60482060A681Q37256080-5A8990F1-B833-4FB7-B4EA-D7DBACA2543CQ37637750-FA7293B4-F927-44FD-9611-24D2FE896295Q38026790-73041158-DFA6-45FC-9CF3-2AC30742F0CBQ38185075-52365C9A-802A-4A5C-9302-BBCC8369AD36Q38212376-12CAE9A5-2D28-4B0B-BE5B-21B2C3E7DD16Q38469671-89A64D14-9E33-4790-8CF7-7C270D5E0E1BQ38669685-B98BD9EF-473C-465E-BF03-190BD5F4265CQ47877991-7E1D402B-76E3-4671-A1B6-B90C3DFA344CQ50182799-E0CB0A6C-43CD-4A60-90C1-BE0652743A6DQ53692390-814D12B0-22AC-428C-8BA5-DA2BFEB285E5
P2860
Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Increasing 2-arachidonoyl glyc ...... n a model of bone cancer pain.
@ast
Increasing 2-arachidonoyl glyc ...... n a model of bone cancer pain.
@en
type
label
Increasing 2-arachidonoyl glyc ...... n a model of bone cancer pain.
@ast
Increasing 2-arachidonoyl glyc ...... n a model of bone cancer pain.
@en
prefLabel
Increasing 2-arachidonoyl glyc ...... n a model of bone cancer pain.
@ast
Increasing 2-arachidonoyl glyc ...... n a model of bone cancer pain.
@en
P2093
P2860
P1476
Increasing 2-arachidonoyl glyc ...... n a model of bone cancer pain.
@en
P2093
Anisha Chandiramani
Catherine Harding-Rose
Donald A Simone
Iryna A Khasabova
Virginia S Seybold
P2860
P356
10.1016/J.PHRS.2011.03.007
P577
2011-04-02T00:00:00Z